Skip to main content
SpringerLink
Log in

Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease

  • Full Papers
  • Published:
Journal of Neural Transmission / General Section JNT Aims and scope Submit manuscript

Summary

Current antiparkinsonian therapies focus on either replacing dopamine via precursor (L-DOPA) administration, or directly stimulating postsynaptic dopamine receptors with dopamine agonists. Unfortunately, this approach is associated with numerous side effects and these drugs lose efficacy with disease progression. This article reviews recent evidence which suggests that negative modulation of glutamatergic neurotransmission has antiparkinsonian effects in a variety of rodent and primate models of parkinsonism. The pronounced synergism between dopaminergic agents and glutamate receptor antagonists may provide a means of using very low doses of the two drug classes in concert to treat Parkinson's disease effectively and minimize dose-related drug side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Albin RL, Aldridge JW, Young AB, Gilman S (1989 a) Feline subthalamic nucleus neurons contain glutamate-like but not GABA-like or glycine-like immunoreactivity. Brain Res 491: 185–188

    Google Scholar 

  • Albin RL, Young AB, Penney JB (1989 b) The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366–375

    Google Scholar 

  • Albin RL, Makowiec RL, Hollingsworth Z, Dure LS, Penney JB, Young AB (1991) Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience 46: 35–48

    Google Scholar 

  • Ambrosio S, Blesa R, Mintenig GM, Palacios AL, Many N, Gual A (1988) Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines in heart, adrenal gland, retina, and caudate nucleus of the cat. Toxicol Lett 44: 1–6

    Google Scholar 

  • Anden NE (1967) Effects of reserpine and a tyrosine hydroxylase inhibitor on the monoamine levels in different regions of the rat central nervous system. Eur J Pharmacol 1: 1–15

    Google Scholar 

  • Bankiewicz KS, Oldfield EH, Chiueh CC, Doppman JL, Jacobowitz DM, Kopin IJ (1986) Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 39: 7–16

    Google Scholar 

  • Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249: 1436–1438

    Google Scholar 

  • Birkmayer W, Hornykiewicz O (1961) Der L-2,3-dioxyphenylalanin (L-Dopa)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787–788

    Google Scholar 

  • Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR (1991) Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord 6 (2): 133–138

    Google Scholar 

  • Burns RS, Markey SP, Phillips JM, Chiuen CC (1984) The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man. Can J Neurol Sci 11: 166–168

    Google Scholar 

  • Carlsson A, Lindquist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180: 1200

    Google Scholar 

  • Carlsson M, Carlsson A (1989) Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J Neural Transm 77: 65–71

    Google Scholar 

  • Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia — implications for schizophrenia and Parkinson's disease. Trends Neurosci 13: 272–276

    Google Scholar 

  • Carlsson M, Svensson A, Carlsson A (1992) Interactions between excitatory amino acids, catecholamines and acetylcholine in the basal ganglia. In: Simon RP (ed) Excitatory amino acids. Thieme, New York, pp 189–194

    Google Scholar 

  • Close SP, Elliott PJ, Hayes AG, Marriott AS (1990) Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. Psychopharmacology 102: 295–300

    Google Scholar 

  • Colpaert FC (1987) Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 26: 1431–1440

    Google Scholar 

  • Cotzias GC, Vanwoert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 2767: 374–379

    Google Scholar 

  • Crossman AR, Peggs D, Boyce S, Luquin MR, Sambrook MA (1989) Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology 28: 1271–1273

    Google Scholar 

  • Crossman AR, Mitchell IJ, Brotchie JM, Aziz TZ, Graham WC, Robertson R, Sambrook MA (1992) Excitatory amino acid transmission of subthalamic nucleus efferents: relationship to hyperkinetic movement disorders and to parkinsonism. In: Simon RP (ed) Excitatory amino acids. Thieme, New York, pp 199–202

    Google Scholar 

  • Eaker EY, Bixler GB, Dunn AG, Moreshead WV, Mathias JR (1987) Chronic alterations in jejunal myoelectric activity in rats due to MPTP. Am J Physiol 253: 809–815

    Google Scholar 

  • Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38: 1236–1239

    Google Scholar 

  • Eidelberg E, Brooks BA, Morgan WW, Waiden JG, Kokemoor RH (1986) Variability and functional recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys. Neuroscience 18: 817–822

    Google Scholar 

  • Freed WJ, Morihasa JM, Spoor E, Hoffer BJ, Olson L, Seiger A, Wyatt RJ (1981) Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behavior. Nature 292: 351–352

    Google Scholar 

  • Gerfen CR (1992) The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 15: 133–139

    Google Scholar 

  • Graham WC, Robertson RG, Sambrook MA, Crossman AR (1990) Injection of excitatory amino acid antagonists into the medial pallidal segment of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sci 47: PL 91-PL 97

    Google Scholar 

  • Greenamyre JT, O'Brien CF (1991) NMDA antagonists in the treatment of Parkinson's disease. Arch Neurol 48: 977–981

    Google Scholar 

  • Hassler R (1938) Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol 48: 387–476

    Google Scholar 

  • Johannesen JN, Goldstein DS, Oliver J, Markey SP (1990) Prolonged changes in plasma concentrations of catecholamine metabolites following a single infusion of an MPTP analog. Life Sci 47: 1895–1901

    Google Scholar 

  • Klockgether T, Turski L (1989) Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci 12: 285–286

    Google Scholar 

  • Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 28: 539–546

    Google Scholar 

  • Klockgether T, Turski L, Honore T, Zhang Z, Gash DM, Kurlan R, Greenamyre JT (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine depleted rats and MPTP treated monkeys. Ann Neurol 30: 717–723

    Google Scholar 

  • Kurlan R (1987) Practical therapy of Parkinson's disease. Semin Neurol 7: 160–166

    Google Scholar 

  • Kurlan R, Kim MH, Gash DM (1991 a) Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov Disord 6 (2): 111–118

    Google Scholar 

  • Kurlan R, Kim MH, Gash DM (1991 b) The time course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys. Ann Neurol 29: 677–679

    Google Scholar 

  • Langston JW (1985) MPTP and Parkinson's disease. Trends Neurosci 8: 79–83

    Google Scholar 

  • Löschmann PA, Lange KW, Kunow M, Rettig KJ, Jahnig P, Honore T, Turski L, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease. J Neural Transm [PD Sect] 3: 203–213

    Google Scholar 

  • Maurissen JPJ, Weiss B, Davis HT (1983) Somatosensory thresholds in monkeys exposed to acrylamide. Toxicol Appl Pharmacol 71: 266–279

    Google Scholar 

  • Miller WC, DeLong MR (1987) Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter MB, Jayarman A (eds) The basal ganglia II. Plenum Press, New York, pp 415–427

    Google Scholar 

  • Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA, Crossman AR (1989) Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32: 213–226

    Google Scholar 

  • Morrison AB, Webster RA (1973) Drug-induced experimental parkinsonism. Neuropharmacology 12: 715–724

    Google Scholar 

  • Pan HS, Walters JR (1988) Unilateral lesion of the nigrostriatal pathway decreases the firing rate and alters the firing pattern of globus pallidus neurons in the rat. Synapse 2: 650–659

    Google Scholar 

  • Robledo P, Feger J (1990) Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: electrophysiological data. Brain Res 518: 47–54

    Google Scholar 

  • Sellal F, Hirsch E, Lisovoski F, Mutschler V, Collard M, Marescaux C (1992) Contralateral disappearance of parkinsonian signs after subthalamic hematoma. Neurology 42: 255–256

    Google Scholar 

  • Smith Y, Parent A (1988) Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity. Brain Res 453: 353–356

    Google Scholar 

  • Smith-Carliss RD, Zhang Z, Kurlan R, McDermott M, Gash DM (1992) Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience (in press)

  • Sommer BK, Keinanen TA, Verdoorn TA, Wisden W, Burnashev N, Herb A, Kohler M, Takagi T, Sakmann B, Seeburg PH (1990) Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science 249: 1580–1585

    Google Scholar 

  • Ungerstedt U (1968) 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5: 107–110

    Google Scholar 

  • Vicini S, Mereu G, Costa E (1992) Synaptic currents mediated by glutamate in dopaminergic substantia nigra pars compacta neurons. In: Simon RP (ed) Excitatory amino acids. Thieme, New York, pp 133–138

    Google Scholar 

Download references

Author information

Author notes

  1. J. T. Greenamyre

    Present address: Departments of Neurology, Neurobiology and Anatomy, and Pharmacology, University of Rochester, Rochester, NY, USA

Authors and Affiliations

    Authors
    1. J. T. Greenamyre
      View author publications

      You can also search for this author in PubMed Google Scholar

    Rights and permissions

    Reprints and permissions

    About this article

    Cite this article

    Greenamyre, J.T. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J. Neural Transmission 91, 255–269 (1993). https://doi.org/10.1007/BF01245235

    Download citation

    • Received:

    • Accepted:

    • Issue Date:

    • DOI: https://doi.org/10.1007/BF01245235

    Keywords

    Search

    Navigation